Literature DB >> 7825656

Case report: inhalation therapy of paromomycin is effective for respiratory infection and hypoxia by cryptosporidium with AIDS.

H Mohri1, H Fujita, Y Asakura, K Katoh, R Okamoto, J Tanabe, H Harano, T Noguchi, Y Inayama, T Amano.   

Abstract

A 24-year-old man with AIDS and hemophilia A had intractable diarrhea and fever. Upon examination of stool and of a sigmoidal biopsy specimen, cryptosporidium was revealed. Approximately 2 months after admission, respiratory infection with hypoxia due to cryptosporidium developed. Paromomycin inhalation was effective therapy. To the authors' knowledge, this is the first case of respiratory cryptosporidiosis treated successfully by paromomycin inhalation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7825656     DOI: 10.1097/00000441-199501000-00009

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  4 in total

1.  Oral nitazoxanide and paromomycin inhalation for systemic cryptosporidiosis in a patient with AIDS.

Authors:  X de la Tribonnière; M Valette; S Alfandari
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

Review 2.  Respiratory cryptosporidiosis: case series and review of the literature.

Authors:  A Clavel; A C Arnal; E C Sánchez; J Cuesta; S Letona; J A Amiguet; F J Castillo; M Varea; R Gómez-Lus
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

Review 3.  The evolution of respiratory Cryptosporidiosis: evidence for transmission by inhalation.

Authors:  Jerlyn K Sponseller; Jeffrey K Griffiths; Saul Tzipori
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

4.  Expectoration of Cryptosporidium Parasites in Sputum of Human Immunodeficiency Virus-Positive and -Negative Adults.

Authors:  Siobhan M Mor; Luke R Ascolillo; Ritah Nakato; Grace Ndeezi; James K Tumwine; Alphonse Okwera; Jerlyn K Sponseller; Saul Tzipori; Jeffrey K Griffiths
Journal:  Am J Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.345

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.